Price$2.77+0.01 (+0.36%)
01:30 PM07:45 PM
News · 26 weeks55+100%
2025-12-142026-06-07
Mix4490d
- SEC Filings13(30%)
- Insider12(27%)
- Other11(25%)
- Analyst6(14%)
- Offering1(2%)
- Leadership1(2%)
Latest news
25 items- INSIDERSr. Vice President and COO Zedelmayer Christine exercised 14,584 shares at a strike of $0.79 and sold $42,737 worth of shares (14,584 units at $2.93) as part of a pre-agreed trading plan (SEC Form 4)4 - Equillium, Inc. (0001746466) (Issuer)
- INSIDERPresident and CSO Connelly Stephen sold $723,830 worth of shares (230,975 units at $3.13), decreasing direct ownership by 23% to 762,025 units (SEC Form 4)4 - Equillium, Inc. (0001746466) (Issuer)
- PREquillium Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)LA JOLLA, Calif., June 02, 2026 (GLOBE NEWSWIRE) -- Equillium, Inc. (NASDAQ:EQ), a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders, today announced that on June 1, 2026, the Compensation Committee of Equillium's Board of Directors granted an inducement award consisting of nonstatutory stock options to purchase a total of 145,000 shares of common stock to a new employee under Equillium's 2024 Inducement Plan. The Compensation Committee approved the stock option as an inducement material to such employee's employment in accordance with Nasdaq Listing Rule 5635(c)(4). The stock option has an exercise price per share equal to $3.08, Equ
- INSIDERPrincipal Accounting Officer Tom Penny sold $191,750 worth of shares (65,000 units at $2.95) as part of a pre-agreed trading plan and exercised 65,000 shares at a strike of $0.79 (SEC Form 4)4 - Equillium, Inc. (0001746466) (Issuer)
- INSIDERSEC Form 4 filed by Director Demski Martha J4 - Equillium, Inc. (0001746466) (Issuer)
- INSIDERSEC Form 4 filed by Director Pruzanski Mark4 - Equillium, Inc. (0001746466) (Issuer)
- INSIDERSEC Form 4 filed by CHAIRMAN Bradbury Daniel4 - Equillium, Inc. (0001746466) (Issuer)
- INSIDERSr. Vice President and COO Zedelmayer Christine sold $267,209 worth of shares (95,833 units at $2.79) as part of a pre-agreed trading plan and exercised 95,833 shares at a strike of $0.77 (SEC Form 4)4 - Equillium, Inc. (0001746466) (Issuer)
- INSIDERSEC Form 4 filed by Director Mcdermott Charles Douglas4 - Equillium, Inc. (0001746466) (Issuer)
- INSIDERSEC Form 4 filed by Director Troupin Barbara4 - Equillium, Inc. (0001746466) (Issuer)
- SECSEC Form 8-K filed by Equillium Inc.8-K - Equillium, Inc. (0001746466) (Filer)
- PREquillium to Participate in the 2026 Jefferies Global Healthcare ConferenceLA JOLLA, Calif., May 28, 2026 (GLOBE NEWSWIRE) -- Equillium, Inc. (NASDAQ:EQ), a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders, today announced that management will participate in a fireside chat at the 2026 Jefferies Global Healthcare Conference on Wednesday, June 3, 2026 at 4:55pm EDT. Members of the Equillium management team will be available to meet with investors who are registered to attend the conference. About EquilliumEquillium is a biotechnology innovator with a mission to develop highly impactful therapies to treat severe autoimmune and inflammatory disorders. For more information, visit www.equilliumbio.com.
- ANALYSTEquillium upgraded by Leerink Partners with a new price targetLeerink Partners upgraded Equillium from Market Perform to Outperform and set a new price target of $6.00
- PREquillium to Host Virtual Investor Event to Share New Insights into the Aryl Hydrocarbon Receptor (AhR) and miR-124 AxisLA JOLLA, Calif., May 20, 2026 (GLOBE NEWSWIRE) -- Equillium, Inc. (NASDAQ:EQ), a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders, today announced it will host a virtual investor event on Wednesday, May 27, 2026, at 11:00 AM ET. The event will be presented by Stephen Connelly Ph.D., Equillium's Chief Scientific Officer, and include new preclinical data evaluating several clinically relevant AhR modulators and further characterization of the relationship between AhR activation and miR-124 induction in both immune and epithelial cells. AhR is a xenosensor essential for maintaining intestinal barrier function and immune homeostasis an
- SECSEC Form 10-Q filed by Equillium Inc.10-Q - Equillium, Inc. (0001746466) (Filer)
- SECEquillium Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Equillium, Inc. (0001746466) (Filer)
- PREquillium Reports First Quarter 2026 Financial Results and Corporate HighlightsPhase 1 proof-of-mechanism study of EQ504 on track to initiate in mid-2026, with data expected approximately six months thereafter Equillium appoints Snehal Naik, Ph.D., as Chief Development Officer to lead clinical development and medical strategy Cash and cash equivalents expected to fund currently planned operations into 2029 LA JOLLA, Calif., May 13, 2026 (GLOBE NEWSWIRE) -- Equillium, Inc. (NASDAQ:EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory disorders, today reported financial results for the first quarter ended March 31, 2026, and provided a corporate update hi
- SECSEC Form SCHEDULE 13G filed by Equillium Inc.SCHEDULE 13G - Equillium, Inc. (0001746466) (Subject)
- PREquillium Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)LA JOLLA, Calif., May 01, 2026 (GLOBE NEWSWIRE) -- Equillium, Inc. (NASDAQ:EQ), a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders, today announced that on May 1, 2026, the Compensation Committee of Equillium's Board of Directors granted inducement awards consisting of nonstatutory stock options to purchase an aggregate of 800,000 shares of common stock to two new employees under Equillium's 2024 Inducement Plan. The Compensation Committee approved the stock option grants as an inducement material to such employees' employment in accordance with Nasdaq Listing Rule 5635(c)(4). Each stock option has an exercise price per share equal t
- ANALYSTOppenheimer initiated coverage on Equillium with a new price targetOppenheimer initiated coverage of Equillium with a rating of Outperform and set a new price target of $7.00
- PREquillium to Participate in Oppenheimer's 2026 Innovation on the Island EventLA JOLLA, Calif., April 20, 2026 (GLOBE NEWSWIRE) -- Equillium, Inc. (NASDAQ:EQ), a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders, today announced that management will be presenting at Oppenheimer's 2026 Innovation on the Island Event on Tuesday April 28, 2026 at 7:50am AST. Members of the Equillium management team will be available to meet with investors who are registered to attend the conference. About EquilliumEquillium is a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders. The company's lead therapeutic candidate is EQ504, a potent and selective aryl hydrocarbon recepto
- SECSEC Form EFFECT filed by Equillium Inc.EFFECT - Equillium, Inc. (0001746466) (Filer)
- ANALYSTB. Riley Securities initiated coverage on Equillium with a new price targetB. Riley Securities initiated coverage of Equillium with a rating of Buy and set a new price target of $6.00
- SECSEC Form DEFA14A filed by Equillium Inc.DEFA14A - Equillium, Inc. (0001746466) (Filer)
- SECSEC Form DEF 14A filed by Equillium Inc.DEF 14A - Equillium, Inc. (0001746466) (Filer)
EQ FAQ
7 questionsWhat does Equillium Inc. do?
Equillium, Inc., a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. Its primary product candidate is itolizumab, a clinical-stage monoclonal antibody that targets the novel immune checkpoint receptor CD6, which is in Phase 1b/2 clinical trials for the treatment of acute graft-versus-host disease; and Phase 1 clinical trial for the treatment of asthma and lupus nephritis. The company was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its name to Equillium...Where does EQ stock trade?
Equillium Inc. (EQ) is listed on NASDAQ.What sector and industry is EQ in?
Equillium Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Equillium Inc. go public?
Equillium Inc. (EQ) completed its IPO in 2018.What are analysts saying about EQ?
Equillium Inc. has had 8 recent analyst actions on file. The most recent action was from Leerink Partners: Outperform with a $600.00 price target on 2026-05-28.What companies are similar to EQ?
Notable peers in the same industry include LLY (Eli Lilly and Company), AZN (AstraZeneca PLC), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare EQ side-by-side with any of them on Quantisnow.How can I track EQ on Quantisnow?
Quantisnow aggregates Equillium Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow EQ to receive live email and push alerts on every new disclosure.